Adenocarcinoma of the Esophagus Withdrawn Phase 1 / 2 Trials for Oxaliplatin (DB00526)

IndicationStatusPhase
DBCOND0030040 (Adenocarcinoma of the Esophagus)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03307941Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CATreatment
NCT02344810C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal CancerTreatment